Vanda B. A.
- Country
- Latvia
- Department
- n/a
Research Overview
- Evaluation of Long-term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Patients with Moderate-to-Severe Plaque Psoriasis
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ESK-001 and Apremilast in Moderate to Severe Plaque Psoriasis Patients
- Long-term Safety, Efficacy, and Response Durability of Envudeucitinib in Moderate to Severe Plaque Psoriasis: An Extension Study
Data & Insights
Has run more than one trial at 120 of 205 partner sites.
Specializations
Dermatological Research
The investigator specializes in advancing therapeutic solutions for chronic skin conditions, with a primary focus on moderate to severe plaque psoriasis.
- Inflammatory skin disorders
- Long-term disease management
- Systemic treatment approaches
Key interests include evaluating novel oral therapeutic agents and their long-term safety profiles in dermatological conditions.
Clinical Assessment
Expertise in conducting long-term safety and tolerability studies for innovative therapeutic compounds in dermatology. Focuses on evaluating treatment durability and patient response patterns.
- Treatment effectiveness monitoring
- Safety profile assessment
- Response durability evaluation
Specialized in assessing therapeutic interventions through controlled clinical environments for chronic skin conditions.
Therapeutic Development
Contributes to the advancement of novel therapeutic options for dermatological conditions through comparative effectiveness research and placebo-controlled studies.
- Comparative treatment assessment
- Therapeutic efficacy evaluation
- Treatment optimization strategies
Involved in evaluating breakthrough treatments for chronic inflammatory skin conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.